The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B. 1.1. 529),
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …

Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus–2 (SARS-CoV-2)
infection, or Long COVID, is a prevailing second pandemic with nearly 100 million affected …

The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed
the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide …

Vaccines developed against SARS-CoV-2 have proven to be highly effective in preventing
symptomatic infection. Similarly, prior infection with SARS-CoV-2 has been shown to provide …

New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications | NEJM Skip to
main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare …

Background The rates of death are high among patients with coinfection with tuberculosis
and the human immunodeficiency virus (HIV). The optimal timing for the initiation of …

Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …

Abstract SARS-CoV-2 Omicron (B. 1.1. 529) BA. 4 and BA. 5 sub-lineages, first detected in
South Africa, have changes relative to Omicron BA. 1 including substitutions in the spike …

Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach
to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally …

Background We previously reported that integrating antiretroviral therapy (ART) with
tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during …